American Oncology Network, LLC (AON) is pleased to announce that The Center for Cancer and Blood Disorders (CCBD), a leading community oncology and hematology practice serving Bethesda and Germantown, Maryland, has joined AON.
Fort Myers, Fla., May 4, 2020 — American Oncology Network, LLC (AON) is pleased to announce that The Center for Cancer and Blood Disorders (CCBD), a leading community oncology and hematology practice serving Bethesda and Germantown, Maryland, has joined AON, effective May 1, 2020. AON is an alliance of physicians and veteran healthcare leaders uniting to ensure the long-term success of community oncology.
The Center for Cancer and Blood Disorders team includes three medical oncologists providing the highest quality of care, with state-of-the-art technology, and the latest advances in clinical research and therapies. The practice regularly performs more than 300 clinical trials on new and developing diagnostic devices and techniques for cancer and diseases. The partnership with AON will help expand patient services such as home delivery of oral oncolytic medications, patient education, and 24/7 pharmacy assistance.
AON CEO Brad Prechtl, MBA stated, “We are excited for Drs. Boccia, Priego and Goldstein and the entire Center for Cancer and Blood Disorders team to join our growing network of community oncologists helping to bring the very best in cancer care and treatment to patients, close to where they live.”
“The Center for Cancer and Blood Disorders will remain focused on integrating the best medicine in an environment that helps patients overcome obstacles such as easier access to medications and financial counseling,” said AON Board Member & Chairman Dr. Stephen Orman.
For more information, read the full press release here.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More